These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 9053475)
1. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. Watts MJ; Sullivan AM; Jamieson E; Pearce R; Fielding A; Devereux S; Goldstone AH; Linch DC J Clin Oncol; 1997 Feb; 15(2):535-46. PubMed ID: 9053475 [TBL] [Abstract][Full Text] [Related]
2. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381 [TBL] [Abstract][Full Text] [Related]
3. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. Watts MJ; Sullivan AM; Leverett D; Peniket AJ; Perry AR; Williams CD; Devereux S; Goldstone AH; Linch DC J Clin Oncol; 1998 Apr; 16(4):1554-60. PubMed ID: 9552065 [TBL] [Abstract][Full Text] [Related]
4. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609 [TBL] [Abstract][Full Text] [Related]
5. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. Smith RJ; Sweetenham JW Exp Hematol; 1995 Dec; 23(14):1581-8. PubMed ID: 8542950 [TBL] [Abstract][Full Text] [Related]
6. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622 [TBL] [Abstract][Full Text] [Related]
7. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor. Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727 [TBL] [Abstract][Full Text] [Related]
8. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Watts MJ; Ings SJ; Leverett D; MacMillan A; Devereux S; Goldstone AH; Linch DC Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877 [TBL] [Abstract][Full Text] [Related]
9. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827 [TBL] [Abstract][Full Text] [Related]
10. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. Jones HM; Jones SA; Watts MJ; Khwaja A; Mills W; Fielding A; Goldstone AH; Linch DC J Clin Oncol; 1994 Aug; 12(8):1693-702. PubMed ID: 7518861 [TBL] [Abstract][Full Text] [Related]
11. Peripheral blood stem cell mobilization with chemotherapy and granulocyte-colony stimulating factor in patients with hematological malignancies. Watanabe S; Mukaiyama T; Ogawa Y; Kawada H; Ichikawa Y Tokai J Exp Clin Med; 1994 Dec; 19(3-6):143-55. PubMed ID: 7570686 [TBL] [Abstract][Full Text] [Related]
12. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. McQuaker IG; Haynes AP; Stainer C; Anderson S; Russell NH Br J Haematol; 1997 Jul; 98(1):228-33. PubMed ID: 9233591 [TBL] [Abstract][Full Text] [Related]
13. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
15. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant. Hogge DE; Lambie K; Sutherland HJ; Benny WB; Dalal B; Currie C; Barnett MJ; Eaves AC; Eaves CJ Bone Marrow Transplant; 2000 Mar; 25(6):589-98. PubMed ID: 10734292 [TBL] [Abstract][Full Text] [Related]
16. Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. Knauf WU; Koenigsmann MP; Notter M; Hoppe B; Reufi B; Oberberg D; Thiel E; Berdel WE Leuk Lymphoma; 1996 Oct; 23(3-4):305-11. PubMed ID: 9031111 [TBL] [Abstract][Full Text] [Related]
17. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Hohaus S; Goldschmidt H; Ehrhardt R; Haas R Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782 [TBL] [Abstract][Full Text] [Related]
18. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
19. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097 [TBL] [Abstract][Full Text] [Related]
20. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]